Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ProMIS Neurosciences Inc. (PMN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PMN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.08
1 Year Target Price $6.08
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.95% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.22M USD | Price to earnings Ratio - | 1Y Target Price 6.08 |
Price to earnings Ratio - | 1Y Target Price 6.08 | ||
Volume (30-day avg) 3 | Beta -0.03 | 52 Weeks Range 0.38 - 1.59 | Updated Date 08/29/2025 |
52 Weeks Range 0.38 - 1.59 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.07 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.16 | Actual -0.29 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -281.41% | Return on Equity (TTM) -19.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22681144 | Price to Sales(TTM) 5168.19 |
Enterprise Value 22681144 | Price to Sales(TTM) 5168.19 | ||
Enterprise Value to Revenue 3868.08 | Enterprise Value to EBITDA -1.74 | Shares Outstanding 51806500 | Shares Floating 29811013 |
Shares Outstanding 51806500 | Shares Floating 29811013 | ||
Percent Insiders 24.16 | Percent Institutions 25.49 |
Upturn AI SWOT
ProMIS Neurosciences Inc.
Company Overview
History and Background
ProMIS Neurosciences Inc. is a biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). Founded to address the limitations of existing approaches to treating these diseases, which often target amyloid plaques rather than the more toxic oligomeric forms of the protein.
Core Business Areas
- Antibody Therapeutics Development: ProMIS focuses on developing novel antibodies that selectively target misfolded proteins, particularly toxic oligomers of amyloid-beta and TDP-43. Their approach aims to improve treatment efficacy and safety by specifically targeting the disease-causing agents.
- Diagnostic Technologies: Alongside therapeutic development, ProMIS is developing diagnostic tools to identify and quantify toxic oligomers in biological samples. This can aid in patient stratification and treatment monitoring.
- Discovery and Validation: ProMIS uses its proprietary discovery platform to identify unique epitopes on misfolded proteins. They then validate these targets for therapeutic intervention.
Leadership and Structure
ProMIS Neurosciences Inc. is led by a team of scientists and executives with experience in neurodegenerative disease research and drug development. The organizational structure consists of research and development, clinical development, and corporate functions. Dr. Elliot Goldstein is the CEO.
Top Products and Market Share
Key Offerings
- PMN310 (Alzheimer's Disease): PMN310 is a monoclonal antibody designed to selectively target toxic amyloid-beta oligomers in Alzheimer's disease. It is currently in preclinical development. There is no market share currently as it is in preclinical development. Competitors: Eli Lilly (Donanemab), Biogen (Aduhelm, Leqembi), Roche (Gantenerumab).
- ALS Programs: ProMIS is developing antibodies targeting TDP-43 misfolding in ALS. These programs are in the discovery and preclinical stages. There is no market share currently as it is in preclinical development. Competitors: Biogen (Tofersen).
- Parkinson's Disease Programs: ProMIS has research programs targeting misfolded alpha-synuclein in Parkinson's disease. These are in early stages of development. There is no market share currently as it is in preclinical development. Competitors: Biogen, Roche, AbbVie.
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing, driven by an aging population and increasing prevalence of diseases like Alzheimer's, Parkinson's, and ALS. Significant unmet need exists for effective therapies that can slow or halt disease progression.
Positioning
ProMIS is positioned as a developer of highly selective antibody therapeutics targeting toxic oligomers. Their competitive advantage lies in their proprietary discovery platform and focus on precise targeting, potentially leading to improved efficacy and reduced side effects compared to existing approaches.
Total Addressable Market (TAM)
The Alzheimer's disease market alone is projected to reach hundreds of billions of dollars. ProMIS is positioned to capture a share of this market if their therapies prove effective, focusing on earlier stages of the disease by targeting toxic oligomers. The TAM for ALS and Parkinson's is also very large.
Upturn SWOT Analysis
Strengths
- Proprietary discovery platform for identifying and targeting toxic oligomers
- Focus on developing highly selective antibody therapeutics
- Experienced leadership team in neurodegenerative disease research
- Potential for improved efficacy and safety compared to existing approaches
Weaknesses
- Early stage of development with no approved products
- High risk and uncertainty associated with drug development
- Dependence on successful preclinical and clinical trials
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Large and growing market for neurodegenerative disease therapies
- Potential for partnerships with larger pharmaceutical companies
- Advancements in diagnostic technologies for early disease detection
- Increasing understanding of the role of toxic oligomers in disease progression
Threats
- Competition from larger pharmaceutical companies with more resources
- Clinical trial failures
- Regulatory hurdles and delays
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- LLY
- BIIB
- ROCHE.SW
Competitive Landscape
ProMIS faces intense competition from larger pharmaceutical companies with significantly more resources. However, their focus on selective targeting of toxic oligomers could provide a competitive advantage if their approach proves more effective and safer than existing therapies. Its a speculative investment at the moment.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by expansion of preclinical programs and advancement of drug candidates towards clinical trials.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercialization of products. Analyst estimates vary widely due to the inherent uncertainty in drug development.
Recent Initiatives: Recent initiatives include advancing PMN310 towards clinical trials, expanding research programs in ALS and Parkinson's disease, and seeking strategic partnerships.
Summary
ProMIS Neurosciences is a high-risk, high-reward biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases. Their strength lies in their proprietary discovery platform, which allows them to selectively target toxic oligomers. However, they face significant challenges due to their early stage of development, limited financial resources, and competition from larger pharmaceutical companies. Successful clinical trials and strategic partnerships are crucial for their future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investing in biotechnology companies carries significant risk, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProMIS Neurosciences Inc.
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2007-07-17 | CEO, President, Compliance Officer & Director Mr. Neil K. Warma M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | |
Full time employees 7 | |||
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.